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Background: To report Taiwan’s experience in robot-assisted laparoscopic nephroureterectomy (RANU) for upper
tract urothelial carcinoma (UTUC).
Methods: Twenty patients with a diagnosis of renal pelvic or ureteral urothelial carcinoma underwent RANU at
three medical centers. We performed RANU by re-docking the robot after the nephrectomy with or without repositioning
for excision of the distal ureter and bladder cuff.
Results: From November 2010 to July 2013, a total of 20 patients with a mean age of 70.1 +/− 9.9 years (range 43 to
92 years) and mean body mass index (BMI) of 22.9 +/−3.8 kg/m2 underwent RANU for renal pelvic or ureteral urothelial
carcinoma. Mean operative time was 251.6 +/− 126.7 minutes (range 110 to 540 minutes), estimated blood loss was
50.0 +/− 42.9 mL (range 10 to 200 mL), and mean length of hospital stay was 6.7 +/− 2.4 days (range 4 to 12 days).
Pathology data revealed 19 high and one low-grade urothelial carcinoma and staged Ta for three, T1 for five, T2 for five
and T3 for seven. With a mean follow-up of 14.7 months (range 2 to 34 months), three intravesical recurrences
developed in the bladder, and four of them also developed metastatic disease.
Conclusions: The TRUST early experience showed that RANU is a safe and feasible minimally invasive procedure
for UTUC.
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The standard treatment of upper tract urothelial carcinoma
(UTUC) is open nephroureterectomy (NU) with ipsilateral
bladder-cuff excision. Laparoscopic nephroureterectomy
(LNU) has been thought as a feasible technique for treating
UTUC since Clayman et al. reported the first case of LNU
in 1991 [1]. In Taiwan, as many as approximately 10% to
21% of all UCs were UTUC, and the incidence of UTUC
was also greater than in other reports in the world [2,3].
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unless otherwise stated.medicine, is thought to be associated with the higher inci-
dence of UTUC in Taiwan [4,5]. According to the study of
a large cohort with a long-term follow-up, LNU provides
comparable oncological control to traditional open surgery
and has the additional advantages of decreased postopera-
tive narcotic use, shorter hospital stay and a more rapid
convalescence [6-9]. However, the learning curve is steep
and this procedure is time-consuming and technique-
dependent. Recently, the da Vinci™ robot system (Intuitive
Surgical, Sunnyvale, CA, USA) was introduced for sur-
geons to perform laparoscopic operations more easily by
reducing the technical difficulty of intracorporeal suturing.
In Taiwan, the first da Vinci™ robot system was set up in
2006, and robot-assisted radical prostatectomies are per-
formed as routine now in several medical centers [10,11].
Herein, we present perioperative robot-assisted laparo-
scopic nephroureterectomy (RANU) outcomes of ourd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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without repositioning of the patient.
Methods
Six men and fourteen women consecutive patients had
received RANU, the patients were not repositioned after
the nephrectomy, however, the robot was re-docked for
excision of the distal ureter and bladder cuff. Exclusion
criteria included metastatic diseases and locally ad-
vanced diseases such as lymph nodes identified by pre-
operative imaging or bulky primary tumor invasion of
adjacent organs. After inducing general endotracheal
anesthesia, patients were placed in the lateral flank pos-
ition. Pneumoperitoneum was created after using a
mini-laparotomy procedure at the periumbilical region
to approach the peritoneal space and a 12-mm primary
port was inserted. The first 8-mm robotic port was in-
troduced at the lateral rectus margin 3 to 4 cm below
the umbilicus. The second 8-mm robotic port was set
up at the midclavicular line two finger breadths below
the twelfth rib. One 12-mm assistant working port was
inserted midway between the umbilicus and symphysis
pubis (Figure 1). Another 5-mm assistant port was created
midway between the umbilicus and xiphoid process. We
identified the renal hilum by identifying the gonadal ves-
sels and ureter. The renal pedicles were dissected, and the
renal artery and vein were divided using Hem-o-Lok
(Teleflex Medical, Raleigh, NC, USA) or endovascular
stapler. The kidney was dissected completely and the
ureter was dissected to the level of the bladder. After
the radical nephrectomy was completed, the robot was
re-docked to manage the distal ureter. We switched
the port for the first robotic instrument arm to the 12-
mm assistant port, and the port for the second robotic
instrument arm to the port for the first arm (Figure 2).
The assistant port, which allowed a 12-mm port to be
inserted with an 8-mm robotic port, was converted to
the port for the second arm as reported by Park et al.Figure 1 Port design for nephrectomy.[12]. The ureteric orifice defect was closed in two
layers with 3 to 0 Monocryl (Ethicon, Guaynabo, Puerto
Rico) sutures. Then, we tested the integrity of the bladder
closure by filling the bladder with 150 mL of normal sa-
line. The periumbilical wound was extended to 4 cm for
extraction of the kidney and ureter. The specimens were
extracted in an entrapment bag. All RANUs were success-
fully completed with the robot, with no conversion to
open surgery. Adjuvant intravesical chemotherapy and
systemic chemotherapy was not administered after the
nephroureterectomy. The oncologic outcomes, including
survival status, bladder recurrence, and metastasis, were
recorded by re-examination of the patients in outpatient
clinics. The patients were followed up every three months
for the first two years. All patients received a physical
examination every three months, urine cytology, urinaly-
sis, and blood biochemical examinations every six months,
and chest radiography, and intravenous urography or ab-
dominal computed tomography or magnetic resonance
imaging to examine the contralateral upper tract every
year. Cystoscopy follow-up was performed every three
months during the first two years. Further cystoscopy
follow-up was performed every three months during the
first two years and every six months thereafter.
Results
The characteristics and pre- and perioperative data of
the patients are shown in Table 1. Table 2 summarizes
the pathologic results. In all, 20 patients operated on by
four surgeons from the three institutions were analyzed.
There were no perioperative complications in all pa-
tients. On pathologic examination, pT3 urothelial car-
cinoma was identified in seven patients, pT2 in five, pT1
in five and pTa in three. There were no positive surgical
margins in any patient. During the follow-up cystoscopy,
four patients (all pT3 patients) had bladder recurrence as
T1-staged bladder urothelial carcinoma were identified
and managed by transurethral resection and intravesical
Figure 2 Port design for bladder cuff excision.
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three pT3) developed distant metastasis and underwent
systemic chemotherapy. One patient (pT3) died of pul-
monary metastatic disease at the sixth month after RANU.
In summary, the cancer-specific survival rate is 75% at the
follow-up
Discussion
The TRUST experience showed that RANU is a safe and
feasible technique for UTUC. During operations, the op-
erative field is magnified and three-dimensional vision
provides surgeons with the ability to identify the ana-
tomical landmarks more easily. In addition, the robotic
surgical system is helpful for us to overcome the draw-
back of pure laparoscopy by providing the EndoWrist in-
struments that allow us to operate with better depth
perception and with the same dexterity and wrist movement.Table 1 Patient demographic and tumor characteristics
Variables N (%) or mean (range)
Number of patients 20
Gender, M: F 6:14
Mean age, years 70.1 (+/−9.9, range 48-92)
Side, n, R: L 10:10
Mean op time, mins 251.6 (+/−126.7, range 110-540)
Mean EBL, ml 50 (+/−42.9, range10-200)
Mean hospital stay, days 6.7 (+/−2.4, range 4-12)




Mean BMI 22.9 (+/−3.8, range 16-30)
Tumor site Pelvicalyceal: 12 (60)
Ureteral: 5 (25)
Pelvicalyceal-ureteral: 3 (15)
EBL, estimated blood loss; ASA, American Society of Anesthesiologists; BMI,
body mass index.On the other hand, the best advantage of the robot system
in RANU is intracoporeal suturing, which could be applied
to the bladder cuff excision, and bladder suturing. However,
the disadvantages of the da Vinci system include high cost,
the need for training, a lack of tactile sensation, and docking
time.
In the literature, the first case of robot-assisted retro-
peritoneal NU for left ureteral UC was reported in 2006
and Rose et al. suggested a retroperitoneal approach
RANU was feasible [13]. Interestingly, they excised the
bladder cuff by the open method. As mentioned above,
robotic surgery systems could provide a better exposure
and surgeons can manage distal ureter and bladder cuff
by the total robot-assisted technique even in the limited
surgical field. Transperitoneal approach RANU is much
more popular in the major centers in the world. As we
know, retroperitoneal space is limited and relatively
small for a robot system setting, especially in Asian pa-
tients. By transperitoneal RANU, Nanigian et al. [14]
performed distal ureterectomy by a novel technique, in-
cluding instilling the bladder with 250 mL of fluid via a
Foley catheter, and incision and closure of the bladderTable 2 Pathological characteristics of robot-assisted
laparoscopic nephroureterectomy patients
Variables N (%) or mean (range)





Grade High 19 (95)
Low 1 (5)
Mean follow-up, months 14.7 (2–34)
Recurrence Bladder recurrence 3 (15)
Local/retroperitoneal 0 (0)
Distant metastasis 4 (20)
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is co-called the hybrid procedure since they used the
conventional laparoscopic method for the nephrectomy
and the robotic system was only applied while they man-
aged the bladder cuff [14]. Hu et al. performed nine
cases of RANU by two methods. Among the patients,
five were repositioned from the flank position to lithot-
omy after laparoscopic nephrectomy and another four pa-
tients were not [15]. In our series, we performed RANU
by re-docking the robotic system but not repositioning.
Park et al. also reported the technical feasibility of the
RANU using the da Vinci robot system for the entire pro-
cedure. Their technique could replicate the open surgical
technique, and suggested that it is safe and adheres to
oncological principles [12]. They introduced the hybrid-
port technique and completed the RANU without reposi-
tioning the patient and any movement of the patient cart.
In this way, they shortened the operative time, and
enjoyed a better exposure of the distal ureterectomy and
an easier closure of the bladder cuff. Furthermore,
Hemal et al. also performed RANU on 15 patients with
UTUC, and they described the method, which did not
need the patient repositioning or re-docking of the ro-
botic system [16].
Eandi et al. successfully performed RANU in 11 pa-
tients with a mean age of 67.4 years. The perioperative
outcomes such as mean operative time was 326 minutes,
estimated blood loss was 200 mL, and mean length of
hospital stay was 4.7 days. With a mean follow-up of
15.2 months, four patients developed recurrence, and
two ultimately died from metastatic disease [17]. When
comparing the present series with Eandi et al. [17], our
operating time was shorter and estimated blood loss was
less. The hospital stay was longer in the present series
(that is 6.7 vs. 4.7 days), which most probably reflects
differences in practice patterns between the two coun-
tries. Recently, a multi-institutional study from the United
State retrospectively evaluated 43 patients treated with
three- or four-armed robotic techniques based on surgeon
preference. The entirety of all procedures was performed
using either a single or two robot-docking techniques
[18]. At a mean follow-up of 10 months, 21% of patients
experienced disease recurrence on routine surveillance.
Among them, six recurred within the bladder, two within
the retroperitoneum both in patients with high grade pT3
disease, and one developed recurrence of the contralateral
collecting system [18]. Our survival outcomes are compar-
able with previous series. Another Korean team also pre-
sented their intermediate-term follow-up of RANU [19].
Lim et al. performed 19 multiport and 13 laparoendo-
scopic single-site (LESS) RANU and followed them at a
median follow-up of 45.5 months. Our operating time was
similar to that of Lim et al. series [19], however, the mean
estimated blood loss of our series is less, which might bebecause they performed LESS on more than 40% of pa-
tients. Several limitations existed for the present study in
addition to the inherent biases of a retrospective study
and small sample size. The present study represents a
multi-institutional retrospective case series from Taiwan,
which has a high incidence rate of UTUC. As such only
limited conclusions can be drawn for comparative effect-
iveness with other techniques. A prospective randomized
control study with an optimal design comparing RANU
with the traditional open method, conventional laparo-
scopic or hand-assisted laparoscopic techniques would be
warranted to assess the clinical efficacy and cost compari-
son between these methods. Another major limitation is
the short follow-up. The mean follow-up in the present
cohort was only 14.7 months. However, despite these limi-
tations, RANU to treat UTUC in this early experience is
comparable with previous reported outcomes of minim-
ally invasive NU. In Taiwan, the incidence of UTUC is
higher than most Western countries, the Taiwan Robotic
Urological Surgery Team (TRUST) will try to initiate a lar-
ger prospective study and collect and analyze the long-
term oncological outcomes of RANU in the future.
Conclusions
TRUST present the short-term follow-up results in 20
patients treated with RANU for UTUC. The periopera-
tive outcomes in the present study are comparable with
other RANU series. A larger study with longer follow-up
is warranted to further confirm the role of RANU in the
treatment of UTUC.
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